[go: up one dir, main page]

EE04144B1 - Farmatseutiline kompositsioon ja selle kasutamine - Google Patents

Farmatseutiline kompositsioon ja selle kasutamine

Info

Publication number
EE04144B1
EE04144B1 EEP200000232A EEP200000232A EE04144B1 EE 04144 B1 EE04144 B1 EE 04144B1 EE P200000232 A EEP200000232 A EE P200000232A EE P200000232 A EEP200000232 A EE P200000232A EE 04144 B1 EE04144 B1 EE 04144B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
EEP200000232A
Other languages
English (en)
Inventor
Karel Jozef Fran�ois Marc
Maria Albert Carlo Dries Willy
Dina Guido Basstanie Esther
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8228929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE04144(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200000232A publication Critical patent/EE200000232A/et
Publication of EE04144B1 publication Critical patent/EE04144B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775—Nanosized powder or flake, e.g. nanosized catalyst
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200000232A 1997-11-17 1998-11-10 Farmatseutiline kompositsioon ja selle kasutamine EE04144B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203568 1997-11-17
PCT/EP1998/007321 WO1999025354A2 (en) 1997-11-17 1998-11-10 Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters

Publications (2)

Publication Number Publication Date
EE200000232A EE200000232A (et) 2001-06-15
EE04144B1 true EE04144B1 (et) 2003-10-15

Family

ID=8228929

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000232A EE04144B1 (et) 1997-11-17 1998-11-10 Farmatseutiline kompositsioon ja selle kasutamine

Country Status (35)

Country Link
US (3) US6555544B2 (et)
EP (1) EP1033987B1 (et)
JP (1) JP4211965B2 (et)
KR (1) KR100365077B1 (et)
CN (1) CN1160074C (et)
AP (1) AP1228A (et)
AR (1) AR016686A1 (et)
AT (1) ATE239480T1 (et)
AU (1) AU745540B2 (et)
BG (1) BG64747B1 (et)
BR (1) BR9814202A (et)
CA (1) CA2309629C (et)
CZ (1) CZ299107B6 (et)
DE (1) DE69814451T2 (et)
DK (1) DK1033987T3 (et)
EA (1) EA002926B1 (et)
EE (1) EE04144B1 (et)
ES (1) ES2199481T3 (et)
HK (1) HK1029045A1 (et)
HR (1) HRP20000289B1 (et)
HU (1) HU226070B1 (et)
ID (1) ID24981A (et)
IL (1) IL136135A (et)
MY (1) MY117810A (et)
NO (1) NO320384B1 (et)
NZ (1) NZ503295A (et)
OA (1) OA11383A (et)
PL (1) PL192203B1 (et)
PT (1) PT1033987E (et)
SI (1) SI1033987T1 (et)
SK (1) SK285126B6 (et)
TR (1) TR200001282T2 (et)
UA (1) UA72189C2 (et)
WO (1) WO1999025354A2 (et)
ZA (1) ZA9810467B (et)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
SK6412002A3 (en) * 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
JP4848575B2 (ja) * 2000-03-30 2011-12-28 ゼリア新薬工業株式会社 アラントインを配合した安定な液剤
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7560490B2 (en) 2001-01-23 2009-07-14 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
US7097868B2 (en) * 2001-08-23 2006-08-29 Bio-Dar Ltd. Stable coated microcapsules
JP5067998B2 (ja) * 2001-10-30 2012-11-07 ノバルティス アーゲー イロペリドンおよび星形ポリマーのデポー製剤
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
PL375603A1 (en) * 2002-10-25 2005-12-12 Pfizer Products Inc. Depot formulations of arylheterocyclic active agents in the form of a suspension
AR046811A1 (es) * 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
US7906125B2 (en) 2003-09-18 2011-03-15 Boston Scientific Scimed, Inc. Solid or semi-solid therapeutic formulations
US20050064045A1 (en) * 2003-09-18 2005-03-24 Sheng-Ping Zhong Injectable therapeutic formulations
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
JP4836797B2 (ja) 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
JP2009533314A (ja) * 2005-04-13 2009-09-17 ファイザー・プロダクツ・インク ナノ粒子を含む貧溶性薬物を持続放出するための注射用デポ製剤および方法
US20080214808A1 (en) * 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
US8263109B2 (en) 2005-05-09 2012-09-11 Boston Scientific Scimed, Inc. Injectable bulking compositions
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
AR055099A1 (es) * 2005-07-28 2007-08-08 Alza Corp Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
SI1981506T1 (sl) 2006-01-20 2013-08-30 Janssen R&D Ireland Dolgoročno zdravljenje infekcije HIV s TCM278
US20080166411A1 (en) * 2006-04-10 2008-07-10 Pfizer Inc Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
TWI413521B (zh) * 2006-06-23 2013-11-01 Tibotec Pharm Ltd Ｔｍｃ２７８之水性懸浮液
EP2154138B1 (en) 2007-04-19 2015-08-19 Youxin Li Novel compounds for treatment of psychotic disorders, preparation methods and uses thereof
WO2009026621A1 (en) * 2007-08-29 2009-03-05 Alphapharm Pty Ltd Pharmaceutical compound & composition
PL2234617T3 (pl) * 2007-12-19 2021-11-08 Janssen Pharmaceutica Nv Schemat dawkowania związany z długodziałającymi estrami paliperydonu do wstrzykiwań
JP5904941B2 (ja) * 2009-07-31 2016-04-20 アセンディス ファーマ エー／エス 生物分解性ポリエチレングリコール系水不溶性ヒドロゲル
KR101759499B1 (ko) 2009-07-31 2017-07-19 사노피-아벤티스 도이칠란트 게엠베하 지속형 인슐린 조성물
MA33467B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Promédicaments comprenant un conjugué insuline-lieur
US20130053405A1 (en) * 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
WO2011042453A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
NZ599558A (en) 2009-10-30 2014-09-26 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
EP2547206B1 (en) 2010-03-15 2016-05-11 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
CN107625728A (zh) 2010-10-18 2018-01-26 大日本住友制药株式会社 注射用缓释制剂
LT3156056T (lt) 2011-03-18 2024-02-26 Alkermes Pharma Ireland Limited Farmacinės kompozicijos, apimančios sorbitano esterius
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
MX2015012404A (es) 2013-03-13 2016-02-03 Eleven Biotherapeutics Inc Formulaciones de citoquinas quimericas para suministro ocular.
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9452131B2 (en) 2014-03-20 2016-09-27 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
WO2016157061A1 (en) * 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
EP3280416B1 (en) 2015-04-07 2020-04-22 Janssen Pharmaceuticals, Inc. Dosing regimen for missed doses for long-acting injectable paliperidone esters
EA034167B8 (ru) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Фармацевтические композиции леветирацетама пролонгированного высвобождения
AU2018354431B2 (en) 2017-10-27 2024-01-18 Geneora Pharma (Shijiazhuang) Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
JP2021506757A (ja) * 2017-12-14 2021-02-22 スペックジーエックス エルエルシー 微粉化パリペリドンエステルを調製するための一工程粉砕法
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
CN113024546B (zh) * 2019-12-25 2022-06-10 江苏晶立信医药科技有限公司 一种小粒径棕榈酸帕利哌酮的制备方法
US20230414504A1 (en) 2020-08-26 2023-12-28 Shanghai Bocimed Pharmaceutical Co., Ltd. Cariprazine pharmaceutical composition, preparation method and application thereof
US11666697B2 (en) 2020-11-30 2023-06-06 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
PL4025188T3 (pl) 2020-11-30 2024-06-17 Janssen Pharmaceutica Nv Schematy dawkowania związane z preparatami paliperydonu o przedłużonym uwalnianiu do wstrzykiwania
CN116507320A (zh) 2020-11-30 2023-07-28 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
MX2023006368A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
WO2023021008A1 (en) 2021-08-20 2023-02-23 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU179443B (en) 1979-05-11 1982-10-28 Chinoin Gyogyszer Es Vegyeszet Process for producing substituted geminal dihalogeno-derivatives of pyrido-square bracket-1,2-a-square closed-pyrimidines,pyrrolo-square bracket-1,2-a-square bracket closed-pyrimidines and pyrimido-square bracket-1,2,-a-square bracket closed-asepines
US4485107A (en) 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
DE3412080A1 (de) 1984-03-31 1985-10-03 Bayer Ag, 5090 Leverkusen 2-(1h-pyrazol-1-yl)-4-(3h)-chinazolinone enthaltende mikrobizide mittel
US4665075A (en) 1984-12-05 1987-05-12 Janssen Pharmaceutica N.V. Derivatives of hydroxy- or amino-substituted (piperidinylalkyl)quinazolines
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
FR2608942B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2634397B2 (fr) 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US5174930A (en) 1986-12-31 1992-12-29 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions
US5151424A (en) 1987-07-01 1992-09-29 Janssen Pharmaceutica N.V. Pharmacologically active (Bicyclic heterocyclyl)methyl and -hetero) substituted hexahydro-1H-azepines and pyrrolidines
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
JP2935117B2 (ja) 1989-01-31 1999-08-16 百合子 加藤 ナノスフェア製剤
JP2787364B2 (ja) * 1990-03-29 1998-08-13 大塚製薬株式会社 脂溶性ビタミン注射液
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5330739A (en) 1992-12-04 1994-07-19 Sterling Winthrop Inc. Iodinated benzoyl acetals and ketals for x-ray imaging
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5260478A (en) 1992-12-08 1993-11-09 Sterling Winthrop Inc. Iodinated aroyloxy carboxamides
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
TW287160B (et) * 1992-12-10 1996-10-01 Hoffmann La Roche
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
NZ250063A (en) 1992-12-14 1996-03-26 Eastman Kodak Co Iodinated aromatic acid ester derivatives; x-ray contrast compositions
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5322679A (en) 1992-12-16 1994-06-21 Sterling Winthrop Inc. Iodinated aroyloxy esters
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
ATE212830T1 (de) 1993-11-19 2002-02-15 Alkermes Inc Herstellung biologisch abbaubarer, einen biologisch aktiven stoff enthaltender, mikropartikel
DK0729357T3 (da) 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Mikroindkapslede 1,2-benzazoler
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
DE4406139A1 (de) 1994-02-25 1995-08-31 Matthias Werner Magnetische Depotarzneimittel für die perorale Applikation mit verbesserter Resorption der Wirkstoffe
US5488133A (en) 1994-03-10 1996-01-30 Eastman Kodak Company Iodinated aroyloxy ketones
HRP950149A2 (en) * 1994-04-13 1997-06-30 Janssen Pharmaceutica Nv Intranasal antimigrene composition
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
CA2191983A1 (en) 1994-06-24 1996-01-04 Edward R. Bacon 2,4,6-triiodo-5-substituted-amino-isophthalate esters useful as x-ray contrast agents for medical diagnostic imaging
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US5936030A (en) 1994-12-21 1999-08-10 Nanosystems Polyether copolymers and a process for preparing them
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5665330A (en) 1995-02-08 1997-09-09 Nano Systems Llc Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coumarin
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
AU4990696A (en) 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
US5603916A (en) 1995-05-22 1997-02-18 Nano Systems L.L.C. 3 5-bis alkanoyl amino-2 4 6-triiodobenzyl esters
MX9709451A (es) 1995-06-06 1998-02-28 Hoechst Marion Roussel Inc Derivados de benzisoxazol e indazol como agentes antipsicoticos.
US5668196A (en) 1995-08-10 1997-09-16 Nanosystems Llc 3-amido-triiodophenyl esters as x-ray contrast agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998044039A1 (fr) * 1997-03-31 1998-10-08 Nippon Zeon Co., Ltd. Composition comportant un melange de resine synthetique et de caoutchouc copolymere de nitrile, carboxyle et hautement sature
US5988165A (en) 1997-10-01 1999-11-23 Invacare Corporation Apparatus and method for forming oxygen-enriched gas and compression thereof for high-pressure mobile storage utilization
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
AU3900499A (en) 1998-05-18 1999-12-06 Sepracor, Inc. (+)-hydroxyrisperidone compositions and methods
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
DE19909338A1 (de) 1999-03-03 2000-09-07 Wacker Chemie Gmbh Verfahren zur kontinuierlichen Herstellung hochviskoser füllstoffhaltiger Siliconmassen
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
US20080214808A1 (en) 2005-04-25 2008-09-04 Thomas Frederik Ernestine Spittaels Preparation of Aseptic 3-[2-[4-((6-Fluoro-1,2-Benzisoxazol-3-Yl)-1-Piperidinyl]-6,7,8,9-Tetrahydro-9-Hydroxy-2-Methyl-4H-Pyrido[1,2-a]Pyrimidin-4-One Palmitate Ester
US20070197591A1 (en) 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
PL2234617T3 (pl) 2007-12-19 2021-11-08 Janssen Pharmaceutica Nv Schemat dawkowania związany z długodziałającymi estrami paliperydonu do wstrzykiwań
NZ599558A (en) 2009-10-30 2014-09-26 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters

Also Published As

Publication number Publication date
SK6882000A3 (en) 2000-12-11
EE200000232A (et) 2001-06-15
CN1160074C (zh) 2004-08-04
ZA9810467B (en) 2000-05-16
EA002926B1 (ru) 2002-10-31
US20030064998A1 (en) 2003-04-03
UA72189C2 (uk) 2005-02-15
JP4211965B2 (ja) 2009-01-21
IL136135A0 (en) 2001-05-20
PL192203B1 (pl) 2006-09-29
AR016686A1 (es) 2001-07-25
HRP20000289A2 (en) 2000-12-31
ES2199481T3 (es) 2004-02-16
SK285126B6 (sk) 2006-06-01
US6555544B2 (en) 2003-04-29
WO1999025354A2 (en) 1999-05-27
US9320707B2 (en) 2016-04-26
JP2001522890A (ja) 2001-11-20
SI1033987T1 (en) 2003-10-31
NO20002278L (no) 2000-06-28
NO320384B1 (no) 2005-11-28
US20030157180A1 (en) 2003-08-21
KR100365077B1 (ko) 2002-12-18
OA11383A (en) 2004-01-27
NZ503295A (en) 2001-02-23
ID24981A (id) 2000-08-31
PL341092A1 (en) 2001-03-26
HUP0100155A3 (en) 2006-07-28
CZ299107B6 (cs) 2008-04-23
CN1278730A (zh) 2001-01-03
ATE239480T1 (de) 2003-05-15
TR200001282T2 (tr) 2000-09-21
AP2000001809A0 (en) 2000-06-30
CZ20001645A3 (cs) 2000-08-16
DE69814451T2 (de) 2004-03-18
EP1033987A2 (en) 2000-09-13
MY117810A (en) 2004-08-30
DE69814451D1 (de) 2003-06-12
NO20002278D0 (no) 2000-04-28
KR20010023906A (ko) 2001-03-26
CA2309629C (en) 2008-01-22
DK1033987T3 (da) 2003-08-25
HUP0100155A2 (hu) 2001-08-28
EA200000541A1 (ru) 2000-10-30
HRP20000289B1 (en) 2009-06-30
AP1228A (en) 2003-11-12
AU2049199A (en) 1999-06-07
AU745540B2 (en) 2002-03-21
HK1029045A1 (en) 2001-03-23
PT1033987E (pt) 2003-09-30
BG64747B1 (bg) 2006-02-28
WO1999025354A3 (en) 1999-08-19
EP1033987B1 (en) 2003-05-07
HU226070B1 (en) 2008-04-28
IL136135A (en) 2005-09-25
CA2309629A1 (en) 1999-05-27
BR9814202A (pt) 2000-09-26
US20120263795A1 (en) 2012-10-18
BG104422A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
EE200000232A (et) Farmatseutiline kompositsioon ja selle kasutamine
EE04904B1 (et) Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon
ID24654A (id) Formulasi farmasi omeprazola
EE03427B1 (et) Pihusti sõlm ja selle kasutamine
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
FI20002584A (fi) Pigmenttimateriaaleja ja niiden valmistus ja käyttö
ID24196A (id) Komposisi dan penggunaan
BR9707812A (pt) Composto composto farmacêutica e uso do composto
EE200000094A (et) Uued plokk-kopolümeerid ja nende saamine
EE04427B1 (et) Suletud mahuti ja selle kasutamine
EE04119B1 (et) Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod
EE200100314A (et) Meetod farmatseutilise kompositsiooni valmistamiseks, farmatseutiline kompositsioon ja selle kasutamine
EE9900524A (et) N-triasolüül-2-indoolkarboksamiidid ja nende kasutamine CCK-A agonistidena
EE9900545A (et) Farmatseutiline kompositsioon
BR9509688A (pt) Composto e composição farmacêutica
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
BR9507768A (pt) Composição farmacêutica
ID29294A (id) Komposisi farmasi
EE200100051A (et) Vastavast (-)-stereoisomeerist põhiliselt vaba (+)-nortsisapriidi või selle farmatseutiliselt vastuvõetava soola kasutamine ja farmatseutiline kompositsioon
ID25857A (id) Komposisi farmasi
ID18698A (id) Komposisi farmasi
BR9710568A (pt) Composi- o farmac-utica contendo um antagonista 5Hht2c e um antagonista d2
FI982682A0 (fi) Uusi komposiitti ja sen käyttö
DE69812129D1 (de) Gelmaterialien
AU7681498A (en) Pharmaceutical composition and use thereof

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231